REACtiVe-2 Phase 1 Data Show Immune Activation in Pancreatic Cancer Treatment with Mitazalimab
The REACtiVe-2 Phase 1 trial combines mitazalimab with dendritic cell therapy in metastatic pancreatic cancer patients.
The combination was found to be safe and well-tolerated, enhancing systemic and local immune responses.
Half of the patients achieved stable disease after treatment, with increased tumor-infiltrating T cells noted in post-treatment biopsies.